0125 Aurinia lupus nephritis
BioCentury & Getty Images


Lupus nephritis patients gain oral option as FDA approves Aurinia’s Lupkynis 

Inclusion of dosing program in label could extend patent coverage

Jan 24, 2021 | 3:49 AM GMT

FDA’s approval Friday of Lupkynis voclosporin will allow Aurinia to introduce an oral therapy into a new marketplace for drugs to treat lupus nephritis, for which there had

Read the full 611 word article

How to gain access

Continue reading with a
two-week free trial.